Gold prices slip as stronger dollar, Fed rate uncertainty weigh
MELBOURNE - Propanc Biopharma, Inc. (NASDAQ:PPCB), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, reported a significant transformation in its financial position for the fiscal year ended June 30, 2025, according to a press release statement. InvestingPro data shows the company maintains a healthy current ratio of 1.5x and operates with a moderate debt-to-capital ratio of 0.06.
The company’s total assets increased from approximately $72,000 to $19.6 million, primarily attributed to prepaid service contracts for market awareness, advisory, accounting, finance, manufacturing, and R&D activities. Stockholders’ equity improved to $13.9 million from a previous deficit of $3.8 million.
Following its initial public offering and uplisting to Nasdaq on August 14, 2025, Propanc entered into an underwriting agreement with D Boral Capital and completed an offering of 1,000,000 common shares, generating gross proceeds of $4 million. The stock has shown significant volatility, trading between $1.25 and $145.46 over the past 52 weeks, with a notable 16.47% gain in the past week.
James Nathanielsz, Propanc’s CEO, stated that the company is focused on advancing its lead therapeutic candidate and building its intellectual property portfolio, with various development milestones anticipated by the end of 2025 and throughout 2026. For deeper insights into PPCB’s development potential and additional financial metrics, InvestingPro subscribers have access to over 10 additional ProTips and comprehensive financial analysis tools.
Nathanielsz also indicated plans to create a digital asset treasury of $100 million or more over the next twelve months. The company noted that as of late 2025, over 200 public companies hold digital assets in their treasuries.
Propanc is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. The therapy is based on the science that pancreatic enzymes stimulate biological reactions in the body and could represent a primary defense against cancer.
In other recent news, Propanc Biopharma, Inc. announced that it has received a certificate of grant from the US Patent & Trademark Office for its proenzyme composition patent. This patent specifically covers a potential future clinical dose of its lead asset, PRP. The company highlighted that this is the fourth US patent granted to them, which enhances their intellectual property portfolio. Propanc has filed a total of 90 patents across major jurisdictions for PRP’s application against solid tumors. This development is part of the company’s ongoing efforts to strengthen its intellectual property rights. The patent grant is a significant step in advancing their research and development initiatives. Investors might find this news relevant as it can impact the company’s future clinical and commercial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.